Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Subjects
Brief Summary: This study is a three Part, Phase 1, randomized, dose-escalation, fusion, placebo-controlled, double-blind study to determine the safety, tolerability and Pharmacokinetic (PK) profile of GSK2336805 in healthy subjects and the safety, tolerability, PK, and antiviral profile of GSK2336805 in subjects chronically infected with HCV: i. Single doses in healthy subjects and the effect of food on GSK2336805 PK (Part 1). ii. Repeat doses in healthy subjects (Part 2) iii. Single doses in chronically infected HCV positive subjects (Part 3).


Options:
A: The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24) (Week 72)
B: The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) (Week 36 or Week 60)
C: GSK2336805 safety parameters : adverse events (Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days); GSK2336805 safety parameters: telemetry (Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days); GSK2336805 safety parameters: absolute values and changes over time of hematology, clinical chemistry, urinalysis (Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days); GSK2336805 safety parameters: vital signs (blood pressure, heart rate) (Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days); GSK2336805 safety parameters: electrocardiogram (ECG) parameters (Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days); GSK2336805 PK parameters following single dose administration: area under the plasma concentration curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity) (Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours); GSK2336805 PK parameters following single dose administration: area under the plasma concentration curve over the dosing interval AUC(0-tau)) (Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours); GSK2336805 PK parameters following single dose administration: maximum observed concentration (Cmax) (Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours); GSK2336805 PK parameters following single dose administration: time to maximum observed concentration (tmax) (Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours); GSK2336805 PK parameters following single dose administration: observed concentration at 24h post-dose (C24) (Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours); GSK2336805 PK parameters following single dose administration: terminal half-life (t1/2) (Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours); GSK2336805 PK parameters following single dose administration: lag time (tlag) (Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours); GSK2336805 PK parameters following single dose administration: apparent clearance (CL/F) (Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours); GSK2336805 PK parameters following repeat dose administration:AUC(0-tau) (Day 7 and Day 14); GSK2336805 PK parameters following repeat dose administration: Pre-dose (trough) concentration at the end of the dosing interval Ctau (Day 7 and Day 14); GSK2336805 PK parameters following repeat dose administration: Cmax (Day 7 and Day 14); GSK2336805 PK parameters following repeat dose administration: tmax (Day 7 and Day 14); GSK2336805 PK parameters following repeat dose administration: t1/2, (Day 7 and day 14); GSK2336805 PK parameters following repeat dose administration: CL/F (Day 7 and Day 14); GSK2336805 PK parameters following single dose in HCV infected subjects: AUC(0-infinity) or AUC(0 - tau) (for 48 hours); GSK2336805 PK parameters following single dose in HCV infected subjects: Cmax (for 48 hours); GSK2336805 PK parameters following single dose in HCV infected subjects: C24 (for 48 hours); GSK2336805 PK parameters following single dose in HCV infected subjects: tmax (for 48 hours); GSK2336805 PK parameters following single dose in HCV infected subjects: tlag (for 48 hours); GSK2336805 PK parameters following single dose in HCV infected subjects: CL/F (for 48 hours); HCV Ribonucleic acid (RNA) viral load reduction from baseline during the 24hr and post-dosing following a single dose of GSK2336805 in HCV subjects (at baseline, 24 hours, and for 16 days); HCV RNA change from baseline to nadir (maximum change) in HCV subjects (baseline, and for 16 days); Time course of HCV viral load at baseline, after dosing with GSK2336805, and for greater than or equal to 2 weeks after GSK2336805 dosing (Part 3) (baseline and up to 16 days)
D: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned) (End of trial, 12 weeks after last planned dose)

Answer: C